What is the Need for Prostatic Biomarkers in Prostate Cancer Management?

Martin Spahn, Silvan Boxler, Steven Joniau, Marco Moschini, Bertrand Tombal, Robert Jeffrey Karnes

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.

Original languageEnglish (US)
Article number70
JournalCurrent Urology Reports
Volume16
Issue number10
DOIs
StatePublished - Oct 18 2015

Fingerprint

Prostatic Neoplasms
Biomarkers
Clinical Trials
Costs and Cost Analysis
Survival
Pharmaceutical Preparations
Therapeutics
Medical Overuse

Keywords

  • Biomarkers
  • Genetics
  • Microenvironment
  • Prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Urology

Cite this

What is the Need for Prostatic Biomarkers in Prostate Cancer Management? / Spahn, Martin; Boxler, Silvan; Joniau, Steven; Moschini, Marco; Tombal, Bertrand; Karnes, Robert Jeffrey.

In: Current Urology Reports, Vol. 16, No. 10, 70, 18.10.2015.

Research output: Contribution to journalArticle

Spahn, Martin ; Boxler, Silvan ; Joniau, Steven ; Moschini, Marco ; Tombal, Bertrand ; Karnes, Robert Jeffrey. / What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. In: Current Urology Reports. 2015 ; Vol. 16, No. 10.
@article{148ea8b3ffb74bd3909dd5107e41f24d,
title = "What is the Need for Prostatic Biomarkers in Prostate Cancer Management?",
abstract = "Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.",
keywords = "Biomarkers, Genetics, Microenvironment, Prostate cancer, Treatment",
author = "Martin Spahn and Silvan Boxler and Steven Joniau and Marco Moschini and Bertrand Tombal and Karnes, {Robert Jeffrey}",
year = "2015",
month = "10",
day = "18",
doi = "10.1007/s11934-015-0545-3",
language = "English (US)",
volume = "16",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "10",

}

TY - JOUR

T1 - What is the Need for Prostatic Biomarkers in Prostate Cancer Management?

AU - Spahn, Martin

AU - Boxler, Silvan

AU - Joniau, Steven

AU - Moschini, Marco

AU - Tombal, Bertrand

AU - Karnes, Robert Jeffrey

PY - 2015/10/18

Y1 - 2015/10/18

N2 - Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.

AB - Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.

KW - Biomarkers

KW - Genetics

KW - Microenvironment

KW - Prostate cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84939228106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939228106&partnerID=8YFLogxK

U2 - 10.1007/s11934-015-0545-3

DO - 10.1007/s11934-015-0545-3

M3 - Article

C2 - 26267226

AN - SCOPUS:84939228106

VL - 16

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 10

M1 - 70

ER -